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Abstract
Background: Lymph node metastasis is a critical event in the progression of tongue squamous cell carcinoma (TSCC). 
The identification of biomarkers associated with the metastatic process would provide critical prognostic information 
to facilitate clinical decision making. Previous studies showed that deregulation of manganese superoxide dismutase 
(SOD2) expression is a frequent event in TSCC and may be associated with enhanced cell invasion. The purpose of this 
study is to further evaluate whether the expression level of SOD2 is correlated with the metastatic status in TSCC 
patients.
Methods: We first examined the SOD2 expression at mRNA level on 53 TSCC and 22 normal control samples based on 
pooled-analysis of existing microarray datasets. To confirm our observations, we examined the expression of SOD2 at 
protein level on an additional TSCC patient cohort (n = 100), as well as 31 premalignant dysplasias, 15 normal tongue 
mucosa, and 32 lymph node metastatic diseases by immunohistochemistry (IHC).
Results: The SOD2 mRNA level in primary TSCC tissue is reversely correlated with lymph node metastasis in the first 
TSCC patient cohort. The SOD2 protein level in primary TSCC tissue is also reversely correlated with lymph node 
metastasis in the second TSCC patient cohort. Deregulation of SOD2 expression is a common event in TSCC and 
appears to be associated with disease progression. Statistical analysis revealed that the reduced SOD2 expression in 
primary tumor tissue is associated with lymph node metastasis in both TSCC patient cohorts examined.
Conclusions: Our study suggested that the deregulation of SOD2 in TSCC has potential predictive values for lymph 
node metastasis, and may serve as a therapeutic target for patients at risk of metastasis.
Background
Oral squamous cell carcinoma (OSCC) is a complex dis-
ease arising in various sites. Tumors from these different
sites have distinct clinical presentations and outcomes,
and are associated with different genetic characteristics
[1]. In this study, we focused on tongue SCC (TSCC), one
of the most common sites for OSCCs. The TSCC is sig-
nificantly more aggressive than other forms of OSCCs,
with a propensity for rapid local invasion and spread [2].
Lymph node metastasis is identified as the single most
adverse independent prognostic factor in patients with
OSCC [3]. Currently, the detection of nodal metastasis is
based on clinical and radiographic examination as well as
histopathologic examination of the surgical specimen if a
neck dissection is performed. However , regional lymph
n o d e  m e t a s t a s i s  c a n n o t  a l w a y s  b e  r e l i a b l y  d e t e c t e d  b y
these routine examinations. This points to the immediate
need for new diagnostic strategies to better identify those
tumors with potentially higher metastatic abilities. Since
several genes have been reported in retrospective trials to
yield prognostic information independently of the TNM
classification, it is reasonable to hypothesize that molecu-
lar "fingerprints" could exist that might define sub-groups
of patients with significantly more aggressive disease.
The effects of redox state play important roles in malig-
nancies. Superoxide dismutase 2 (SOD2) has been con-
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sidered as one of the most important antioxidant
enzymes that regulate the cellular redox state in normal
and tumorigenic conditions. Studies suggested that alter-
ation in SOD2 level may influence the metastatic poten-
tial of tumor cells via activating mitogen-activated
protein kinases (MAPK), and regulating the expression of
matrix metalloproteinase (MMP) gene family members
(including MMP-1 and MMP-9) [4-7]. The object of this
study is to evaluate whether the expression level of SOD2
is correlated with metastatic status in TSCC patients. We
first performed pooled-analysis on existing TSCC
microarray datasets to explore the potential associations
between of SOD2 mRNA levels and clinicopathological
characteristics. We then tested an additional independent
TSCC patient group to confirm and further elucidate the
role of SOD2 in TSCC.
Methods
Patients
Two TSCC patient groups (total n = 153), 31 cases of dys-
plasia of the tongue and 15 normal tongue biopsies were
utilized in this study. Clinical characterization of the
patients is summarized in Table 1. The cohort #1 was
used for evaluating the SOD2 expression at mRNA level.
This group consists of 53 TSCC cases and 22 matching
normal tissues where the microarray data were either
generated from our previous study [8] or downloaded
from GEO database [9-11]. The cohort #2 was used for
assessing SOD2 expression at protein level using immu-
nohistochemical assay. This group includes 100 TSCC
patients who underwent surgery at the First Affiliated
Hospital, Sun Yat-Sen University (Guangzhou, China)
between 1998 and 2006. The tumor extent was classified
according to the TNM system by UICC, and the tumor
grade was classified according to the WHO classification
of histological differentiation. Among this 100 TSCC
cases, forty cases were diagnosed with lymph node
metastasis (pN+). Of the 40 pN+ cases, thirty two cases
have available biopsies of the lymph node metastasized
diseases for the immunohistochemical assay. In addition,
31 cases of dysplasia of the tongue and 15 normal tongue
biopsies were also obtained from the same clinic for the
Table 1: Clinical Characterization of the cohorts†
Cohort #1 Cohort #2
TSCC Normal TSCC Premalignant Normal
Age Median (range) 57 (32-82) 56 (37-78) 53 (21-77) 51 (30-82) 47 (30-72)
Gender Male: n (%) 39 (73.58) 13 (59.09) 60 (60.00) 17 (54.84) 6 (40.00)
Female: n (%) 14 (26.42) 9 (40.91) 40 (40.00) 14 (45.16) 9 (60.00)
T stage Stage 4: n (%) 30 (56.60) 6 (6.00)
Stage 3: n (%) 4 (7.55) 15 (15.00)
Stage 2: n (%) 12 (22.64) 51 (51.00)
Stage 1: n (%) 7 (13.21) 28 (28.00)
N stage 
(Pathological)
Stage 2: n (%) 23 (43.40) 18 (18.00)
Stage 1: n (%) 4 (7.55) 22 (22.00)
Stage 0: n (%) 26 (49.05) 60 (60.00)
Clinical stage Stage 4: n (%) 39 (73.58) 21 (21.00)
Stage 3: n (%) 4 (7.55) 27 (27.00)
Stage 2: n (%) 7 (13.21) 26 (26.00)
Stage 1: n (%) 3 (5.66) 26 (26.00)
Grade‡ Well: n (%) NA 51 (51.00)
Mod: n (%) NA 30 (30.00)
Poor: n (%) NA 19 (19.00)
† The M stage data for TSCC patients is not available.
‡ The Grade data is not available for TSCC cohort #1.Liu et al. BMC Cancer 2010, 10:365
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immunohistochemical assay. This study was approved by
the ethical committee at Sun Yat-Sen University, and the
Institutional Review Boards (IRB) at University of Illinois
at Chicago.
Pooled-analysis to extract SOD2 expression values from 
existing microarray datasets
The CEL files from all datasets (53 TSCCs and 22 normal
tongue samples) were imported into the statistical soft-
ware R 2.4.1 [12] using Bioconductor [13]. The pooled-
analysis was performed as described [14], and the
genome-wide expression pattern has been presented in
our previous study [8]. In brief, the Robust Multi-Array
Average (RMA) expression measures [15] were computed
after background correction and quantile normalization
for each microarray dataset. Then, expression values of
the overlapping probesets between U133A and U133 Plus
2.0 arrays were extracted. Probeset-level quantile normal-
ization was performed across all samples to make the
effect sizes similar among the four datasets [14]. The
expression values for probesets corresponding to SOD2
gene (215223_s_at and 216841_s_at) and for Ki67 gene
(212020_s_at, 212021_s_at, 212022_s_at, and
212023_s_at) were then extracted from each datasets.
Relative expression level for SOD2 and Ki67 genes for
each TSCC samples were computed as follows:
First, for every probeset, we found the mean expression
level in normal samples,  , where j  denotes the
probeset. Second, the expression values derived from the
probeset were normalized by the mean normal expres-
sion level, , where i  denotes the TSCC
sample and j denotes the probeset. Third, for every TSCC
sample, the expression value of the gene was assigned by
taking the average over the normalized expression levels
of the probesets representing the same gene,
, where n is the number of probesets for
each gene (n = 2 for SOD2 and n = 4 for Ki67).
Immunohistochemical analysis
Tissue samples were dehydrated in an ethanol series,
cleared in xylene, and embedded in paraffin. Five-
micrometer sections were prepared and mounted on
poly-L-lysine-coated slides. Representative sections were
stained with H&E and histologically evaluated by a
pathologist. Immunohistochemical analysis was done
using a commercially available kit (Invitrogen, Carlsbad,
CA ) .  S e c t i o n s  w e r e  i n c u b a t e d  a t  6 0 ° C  f o r  3 0  m i n  a n d
deparaffinized in xylene. Endogenous peroxidase activity
was quenched by incubation in a 9:1 methanol/30%
hydrogen peroxide solution for 10 min at room tempera-
ture. Sections were rehydrated in PBS (pH 7.4) for 10 min
a t  r oo m  t e m pe r a t u r e .  Sect i o n s  w e r e  b l oc k ed  wi t h  1 0 %
normal serum for 10 min at room temperature followed
by incubation with anti-SOD2 and anti-Ki67 antibodies
(ABCam) at a dilution of 1:200 for 16 h at room tempera-
ture. After washing thrice in PBS, the sections were incu-
bated with secondary antibody conjugated to biotin for
10 min at room temperature. After additional washing in
PBS, the sections were incubated with streptavidin-con-
jugated horseradish peroxidase enzyme for 10 min at
room temperature. Following final washes in PBS, anti-
gen-antibody complexes were detected by incubation
with a horseradish peroxidase substrate solution contain-
ing 3,3'-diaminobenzidine tetrahydrochloride chromo-
gen reagent. Slides were rinsed in distilled water,
coverslipped using aqueous mounting medium, and
allowed to dry at room temperature. The relative intensi-
ties of the completed immunohistochemical reactions
were evaluated using light microscopy by 3 independent
trained observers who were unaware of the clinical data.
All areas of tumor cells within each section were ana-
lyzed. All tumor cells in ten random high power fields
were counted. A scale of 0 to 3 was used to score relative
intensity, with 0 corresponding to no detectable immuno-
reactivity and 1, 2, and 3 equivalent to low, moderate, and
high staining, respectively. As for Ki67, nuclear staining
was evaluated by calculating the percentage of positive
nuclei (Ki67 index).
Statistical analysis
Spearman Correlation Coefficient was used to assess cor-
relations among the gene expression and clinical and his-
topathological parameters. One-way ANOVA was used
to assess the association of SOD2 expression with clinical
and histopathological parameters (e.g., TNM and grade).
The normality of the observed SOD2 expression data
were tested by quantile-quantile plot (QQ plot) (Addi-
tional File 1).
Results
The SOD2 mRNA level in TSCC
Pooled-analysis was performed on previous existing
microarray datasets to determine the SOD2 mRNA levels
in TSCC (n = 53) and normal tongue samples (n = 22). As
illustrated in Figure 1A, the SOD2 expression is signifi-
cantly higher in TSCCs than in normal tissue samples.
The expression level of SOD2 is somewhat higher in late
stage (stage III and IV) than early stage disease (stage I
and II), but the difference is not statistically significant
(Figure 1B). Statistical significant reduction in SOD2
mRNA level was observed in the primary disease tissues
with positive node metastasis status (pN+) as compared
to those with negative status (pN-) (Figure 1C). Increased
SOD2 expression was also observed in larger (T3-4) vs.
smaller (T1-2) primary tumors (Figure 1D).
x jn o r m ,
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The SOD2 protein level in TSCC
To confirm our observations and further elucidate the
r o l e  o f  S O D 2 ,  t h e  e x p r e s s i o n  o f  t h e  S O D 2  g e n e  w a s
examined by immunohistochemistry (IHC) in an addi-
tional TSCC patient cohort (total n = 100), as well as 31
premalignant dysplasias, 15 normal tongue mucosa, and
32 cases of lymph node metastatic disease (Table 2). As
illustrated in Figure 2A, SOD2 IHC staining was sparsely
observed in the cytoplasm of epithelial layers with the
exception of the superficial layers for the normal tongue
tissue. Among 15 normal tongue mucosa samples that we
examined, 9 cases (60%) exhibited weak SOD2 staining, 5
cases (33.3%) exhibited moderate staining, and 1 case
(6.7%) showed no staining. All premalignant dysplasia
cases showed positive IHC staining in all layers of the
mucosa (Figure 2B). The percentage of positive cells and
the staining intensity were increased as compared to nor-
mal mucosa. Of the 31 premalignant cases, 3 cases (9.7%)
showed strong SOD2 staining, 14 cases (45.1%) showed
moderate staining, 11 cases (35.5%) showed weak stain-
ing and 3 cases (9.7%) showed no staining. Among TSCC
primary cases, the intensity of SOD2 staining varied dra-
matically. Of the 100 TSCC samples evaluated, 25 cases
(25%) showed strong SOD2 staining, in 29 cases (29%)
showed moderate staining, 42 cases (42%) showed weak
staining and 4 cases (4%) showed no staining. Predomi-
nantly cytoplasmic staining for SOD2 was observed in
the less-differentiated cells located at the periphery of
carcinomatous clusters but negative staining was
observed for areas of keratin pearls (Figure 2C). For
lymph node metastatic disease, homogeneous staining
involved almost all the metastatic tumor cells in the
affected lymph nodes (Figure 2D). Among 32 lymph node
metastases that we examined, strong staining was
observed in 10 cases (31.25%), moderate staining in 11
cases (34.4%), weak staining in 10 cases (31.25%), and
negative staining in 1 case (3.1%).
Correlation between SOD2 expression and 
clinicopathological characteristics in TSCC
Correlations were tested among gene expression (e.g.,
SOD2 and Ki67), clinical and pathological features for
both TSCC patient groups (Table 3). For patient group #1
(n = 53), the SOD2 mRNA level was positively correlated
with the T stage and inversely correlation with pN. For
patient group #2 (n = 100), the SOD2 protein level was
inversely correlated with pN, clinical stage, differentiation
(grade) and Ki67 index. It is important to notice that of
the 2 patient groups examined (total n = 153), inverse
correlation was consistently observed between SOD2
expression and pN. As illustrated in Table 4, statistical
analysis revealed that the SOD2 expression level in pri-
mary TSCC is associated with pN status in both patient
groups (p = 0.043 and p = 0.0004, respectively).
Discussion and Conclusions
An essential characteristic of cancer is the ability to
invade surrounding tissues and metastasize to regional
lymph nodes and distant sites [16]. Detection of local
lymph node metastasis is pivotal for choosing appropri-
ate treatment, including individuals diagnosed with
OSCC. It is believed that the underlying molecular fea-
tures of the tumors play an essential role in determining
the aggressiveness of the tumors. Previous studies sug-
gested that the deregulation of SOD2 gene expression is a
common even t in OSCC and a ppears t o be associa t ed
with invasion [8,17,18].
In our present study, by focusing on cancer from just
one anatomic site (tongue), we were able to partially min-
imize the genetic variation and microenvironment effects
among intraoral sites. We made two important observa-
tions. First, deregulation of SOD2 gene expression is a
progressive event in the tumorigenesis of TSCC. Our
study confirmed that the SOD2 level is increased in
TSCC when compared to normal tissue. The SOD2 level
is further enhanced in metastatic diseases when com-
pared with primary tumors. Second, the association of
reduced SOD2 expression in primary TSCC and the pres-
ence of lymph node metastasis was consistently observed
in both patient groups. Similar observations have been
made in esophageal cancer and melanoma, where inverse
Figure 1 mRNA expression of SOD2 in TSCC based on pooled-
analysis. Pooled-analysis was performed to extract the relative expres-
sion level of SOD2 mRNA from microarray datasets of 53 TSCCs and 22 
normal control samples as described. Box plots were presented for 
comparing the SOD2 mRNA levels of SCC and normal control samples 
(A), clinical stage I-II and clinical stage III-IV SCC samples (B), SCC sam-
ples with (pN+) and without lymph node metastasis (pN-) (C), and SCC 
samples with different pT stages (D). The p-values were computed us-
ing one-way ANOVA. The boxes represent 25th to 75th percentile of the 
observations, and the lines in the middle of the box represent the me-
dian. The whiskers represent maximum (or minimum) observations 
below (or above) the 1.5 times of the interquartile range (IQR), respec-
tively. Outliers are also indicated in the plots as small circles.Liu et al. BMC Cancer 2010, 10:365
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correlations were observed between SOD2 expression
and metastatic potential of the cancer cells [19,20]. Nev-
ertheless, our sample size (total n = 153) is relatively
small. Further validation studies with larger sample size
and additional stratification to control potential con-
founding factors (e.g., age, gender, ethnicity, smoking his-
tories) are needed to validate our findings.
Accumulating evidence indicates that the deregulations
of the SOD2 expression and the intracellular redox state
play important roles in the progression of TSCC. Our
previous Gene Ontology-based analysis suggested that
redox related biological activities, such as superoxide
release (GO:0042554), hydrogen peroxide metabolism
(GO:0042743), and response to hydrogen peroxide
(GO:0042542), are significantly altered in TSCC [8].
However, the precise roles of SOD2 and redox state in
malignancies are not fully explored. In theory, reducing
the oxidative stress may prevent DNA degeneration and
therefore prevent the development of cancer. However,
doing so may also offer increased growth potential to
tumor cells and protect them from an excess of reactive
oxygen species (ROS), which would otherwise lead to
apoptosis or necrosis. SOD2 is mainly present in the
mitochondrial matrix, where most oxygen is consumed
and oxidative stress is most evident. The role of SOD2 in
carcinogenesis has been widely studied but remains
ambiguous. While some in vitro studies have reported a
protective role of SOD2 against tumor progression in sev-
eral type of cancer cell lines [21-26], in vivo studies sug-
gest more complicated roles of SOD2 in tumorigenesis.
I n c r e a s e d  S O D 2  l e v e l s  h a v e  b e e n  o b s e r v e d  i n  g a s t r i c ,
brain astrocytic, and colorectal carcinomas, and is often
associated with metastasis and poor prognosis [27-35].
The status of SOD2 levels in breast cancer is not clear ,
with some studies showing increased SOD2 [36], while
others showing a decrease in SOD2 [37]. There seems to
be a reduction in SOD2 levels also in prostatic carcino-
mas when compared to healthy tissue [38,39]. It has been
suggested that SOD2 may influence the metastatic poten-
tial of tumor cells via regulating the expression of MMP
gene family members (including MMP-1 and MMP-9) [5-
7]. Interestingly, a single nucleotide polymorphism (SNP)
t h a t  c r e a t e s  a n  E t s  s i t e  a t  t h e  p r o m o t e r  r e g i o n  o f  t h e
MMP-1 gene has been shown to be responsible for the
SOD2 dependent MMP-1 expression [6]. This SNP has
been extensively investigated and has been shown in sev-
eral populations to be associated with OSCC susceptibil-
ity and aggressiveness [40-43]. Studies also showed that
hydrogen peroxide generated by SOD2 can activate
MAPK and transcriptional factors such as c-fos, c-jun
and NFκB [4,44,45]. Further studies are needed to fully
explore the functional roles of these molecular regulators
in the metastasis of TSCC.
In summary, our study confirmed that the SOD2 level is
increased in TSCC when compared to normal tissue. The
S O D 2  l e v e l  i s  f u r t h e r  e n h a n c e d  i n  m e t a s t a t i c  d i s e a s e
when compared with primary tumors. In primary TSCC,
reduced SOD2 expression is associated with presence of
lymph node metastasis. Taken together, our findings sug-
gested that SOD2 may be useful as a biomarker for the
molecular classification of TSCC. Nevertheless, further
validation studies with larger, independent sample sets
Table 2: The protein expression of SOD2 in TSCC†
Strong Moderate Weak No
Normal: n (%) 0 (0.00) 5 (33.33) 9 (60.00) 1 (6.67)
Premalignant: n (%) 3 (9.68) 14 (45.16) 11 (35.48) 3 (9.68)
TSCC: n (%) 25 (25.00) 29 (29.00) 42 (42.00) 4 (4.00)
LN metastasis: n (%) 10 (31.25) 11 (34.38) 10 (31.25) 1 (3.12)
† The SOD2 levels were measured by immunohistochemistry (IHC) on cohort #2. The cases were categorized based on relative SOD2 level (IHC 
staining) as strong, moderate, weak, and no staining.
Figure 2 OD2 expression in normal tongue, premalignant dys-
plasia, primary TSCC and lymph node metastasis tissue samples. 
Immunohistochemical analysis for SOD2 was performed as described 
in the Material and Methods on normal tongue mucosa (A), premalig-
nant dyslasia (B), primary TSCC, and (C) lymph node metastasis tissue 
samples (D). Representative Images (×200) were shown.Liu et al. BMC Cancer 2010, 10:365
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Table 3: Correlations among clinical features and SOD2 gene expression of primary TSCC†
Age Gender pT stage pN stage C stage Grade Ki67‡ SOD2§
Patient cohort # 1 (n = 53)
Age 0.06 -0.07 0.08 0.03 na 0.16 0.14
Gender 0.09 -0.25 -0.07 na 0.01 0.20
pT stage 0.05 0.65 * na -0.18 0.49 *
pN stage 0.49 * na 0.21 -0.28 *
C stage na -0.09 0.19
Grade na na
Ki67 -0.01
SOD2
Patient cohort #2 (n = 100)
Age 0.12 -0.05 -0.10 -0.01 -0.01 -0.01 -0.16
Gender 0.11 0.04 0.11 0.07 -0.05 -0.02
pT stage 0.42 * 0.77 * -0.16 -0.01 0.04
pN stage 0.80 * -0.05 0.09 -0.35 *
C stage -0.07 0.05 -0.21 *
Grade 0.05 -0.30 *
Ki67 -0.28 *
SOD2
† Spearman Correlation Coefficients.
‡ The Ki67 index for Patient Cohort #1 was based on the relative mRNA level. The Ki67 index for Patient Cohort #2 was based on 
Immunohistochemical analysis.
§ The expression levels of SOD2 for Patient Cohort #1 were based on the relative mRNA level. The expression levels of SOD2 for Patient Cohort 
#2 were generated from Immunohistochemical analysis.
* p < 0.05. The p values were computed using Fisher's transformed z-score test.
na: data not available.
Table 4: Association of reduced SOD2 expression in primary TSCC and lymph node metastasis (pN)†
n SOD2‡
Average Variance
Patient Cohort #1
pN + 27 1.18 0.19
pN - 26 1.29 0.21
(p = 0.043)
Patient Cohort #2
pN + 40 1.06 0.57
pN - 60 1.62 0.58
(p = 0.0004)
† One-way ANOVA was used to assess the association of SOD2 with pN.
‡ The expression levels of SOD2 for Patient Cohort #1 were based on the relative mRNA level. The expression levels of SOD2 for Patient Cohort 
#2 were generated from Immunohistochemistry. The p-values were computed using one-way ANOVA.Liu et al. BMC Cancer 2010, 10:365
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and additional stratification to control potential con-
founding factors are needed to validate our findings.
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